Corrections
Correction to Lancet
Diabetes Endocrinol
2019; 7: 356–67
Zinman B, Bhosekar V, Busch R, et al.
Semaglutide once weekly as add-on
to SGLT-2 inhibitor therapy in type 2
diabetes (SUSTAIN 9): a randomised,
placebo-controlled trial. Lancet Diabetes
Endocrinol 2019; 7: 356–67—In
table 3 of this Article, the event
rates of diabetic retinopathy per
100 years of exposure were corrected
for both groups. This change does
not affect the written interpretation.
The legend of table 3 was updated
to add the following footnote, as
related to the fatal adverse events,
diabetic retinopathy, neoplasms, and
cardiovascular events rows: “These
adverse events include events that
had onset, or increase in severity,
from randomisation to either: last
patient–site contact (follow-up visit
at 5 weeks after the end of treatment
visit at week 30), withdrawal if the
patient withdrew informed consent,
last patient–investigator contact
as defined by the investigator for
patients who are lost to follow-up,
or death (in-trial data).”. The Results
text was also updated from “The
most common adverse events in both
groups were gastrointestinal system
disorders” to “The most common
adverse events in the semaglutide
group were gastrointestinal system
www.thelancet.com/diabetes-endocrinology Vol 7 August 2019
disorders”. These corrections have
been made to the online version as of
July 1, 2019.
Correction to Lancet
Diabetes Endocrinol
2019; 7: 417–19
Lean MEJ, Sattar N. Da Qing 30 years
on: more reasons to extend diabetes
prevention. Lancet Diabetes Endocrinol
2019; 7: 417–19—This Comment
was initially published with incorrect
copyright information. This correction
has been made to the online version as
of June 17, 2019.
Correction to Lancet
Diabetes Endocrinol
2019; 7: 590–92
Kehlenbrink S, Jaacks LM, on behalf of the
Boston Declaration signatories. Diabetes
in humanitarian crises: the Boston
Declaration. Lancet Diabetes Endocrinol
2019; 7: 590–92—In this Comment, the
names of two of the Boston Declaration
signatories listed in the appendix
(Eric Lontchi-Yimagou and Ossama
Zaqqout) were spelled incorrectly.
These errors have been corrected in the
online version as of July 16, 2019.
Correction to Lancet
Diabetes Endocrinol
2019; 7: 606–17
Mosenzon O, Wiviott SD, Cahn A, et al. Published Online
Effects of dapagliflozin on development July 1, 2019
http://dx.doi.org/10.1016/
and progression of kidney disease in
patients with type 2 diabetes: an analysis
S2213-8587(19)30220-7
from the DECLARE–TIMI 58 randomised Published Online
June 17, 2019
trial. Lancet Diabetes Endocrinol
http://dx.doi.org/10.1016/
2019; 7: 606–17—In this Article, S2213-8587(19)30219-0
references 19–22 were not cited in the
text. This error has been corrected in
the online version as of July 16, 2019,
and the printed version is correct.
Correction to Lancet
Diabetes Endocrinol 2019;
7: 618–28
Ray KK, Colhoun HM, Szarek M, et al. Published Online
Effects of alirocumab on cardiovascular July 8, 2019
http://dx.doi.org/10.1016/
and metabolic outcomes after acute S2213-8587(19)30242-6
coronary syndrome in patients with or
without diabetes: a prespecified analysis
of the ODYSSEY OUTCOMES randomised
controlled trial. Lancet Diabetes
Endocrinol 2019; 7: 618–28—In the
table of this Article, the units for the
duration of follow-up have been
corrected from “months” to “years”.
This correction has been made to the
online version as of July 8, 2019 and
the printed Article is correct.
e20